COVID19AM: Clinical development and production of vilobelimab as a first-in-class anti-C5 antibody for the treatment of critically ill COVID-19 patients (VILO-COVID)
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:1 publications
Grant number: 16LW0113
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$38,573,185.94Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
InflaRx GmbHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Publicationslinked via Europe PMC
Last Updated:41 minutes ago
View all publications at Europe PMC